摘要为提高我国胰腺癌的总体治疗水平，中华医学会外科学分会胰腺外科学组、中国研究型医院学会胰腺疾病专业委员会组织相关专家制定本指南。本指南基于GRADE系统，针对胰腺癌新辅助治疗的应用指征、方案选择、疗效评估及其相关病理学诊断、手术策略等热点问题展开讨论，对现有临床研究的证据等级量化评估并提出推荐意见，以指导并促进胰腺癌新辅助治疗的临床实践。本指南强调多学科综合治疗协作组的重要地位，体现了胰腺癌治疗理念的转变。新辅助治疗能够有效延长部分胰腺癌患者的生存期，但仍需开展高质量临床研究，以进一步提升证据等级，完善临床实践方案，改善患者预后。

abstractsIn order to improve the overall treatment level of pancreatic cancer in China, Study Group of Pancreatic Surgery in China Society of Surgery of Chinese Medical Association and Pancreatic Disease Committee of China Research Hospital Association have formulated the guideline for neoadjuvant therapy of pancreatic cancer in China (2020 edition). Based on the GRADE system, the guideline has conducted a discussion on the indication, regimen selection, therapeutic effect evaluation, pathological diagnosis and surgery strategy, etc. This guideline has quantified the evidence level of the current clinical researches and provided recommendations for the clinical practice in the neoadjuvant therapy of pancreatic cancer. The guideline has highlighted the role of multiple disciplinary team and represented the conversion of treatment concept in pancreatic cancer. Neoadjuvant therapy has prolonged the survival of the part of pancreatic cancer patients. However, more high-quality clinical researches are in urgent need to improve the level of evidence, optimize the clinical practice and improve the survival of patients.